NCT04363684

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 2,100 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Detailed description

The ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study aims to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohorts longitudinally and informing clinical trial design. The study has two arms: a "longitudinal arm" involving a comprehensive assessment of clinical, functional, imaging, and biofluid data collection annually, and a "biofluid-focused arm" involving limited clinical data to accompany biospecimen collection. For more information: https://www.allftd.org/

Conditions

• Frontotemporal Lobar Degeneration (FTLD)
• Progressive Supranuclear Palsy (PSP)
• Corticobasal Degeneration (CBD)
• Behavioral Variant Frontotemporal Dementia (bvFTD)
• Semantic Variant Primary Progressive Aphasia (svPPA)
• Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
• FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)
• Amyotrophic Lateral Sclerosis
• Oligosymptomatic PSP (oPSP)
• C9orf72
• GRN Related Frontotemporal Dementia
• MAPT Gene Mutation
• TBK1 Gene Mutation
• Oligosymptomatic Progressive Supranuclear Palsy

Timeline

• Start date: 2020-03-01
• Primary completion: 2026-06-30
• Completion: 2026-06-30
• First posted: 2020-04-27
• Last updated: 2025-07-11

Locations

27 sites across 2 countries: United States, Canada